Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. D'Haens G, et al. Among authors: van deventer s, van hootegem pp, van assche g, van bodegraven aa, van der woude j, van de mierop fj. Lancet. 2008 Feb 23;371(9613):660-667. doi: 10.1016/S0140-6736(08)60304-9. Lancet. 2008. PMID: 18295023 Clinical Trial.
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Baert F, et al. Among authors: van assche g. Gastroenterology. 2010 Feb;138(2):463-8; quiz e10-1. doi: 10.1053/j.gastro.2009.09.056. Epub 2009 Oct 8. Gastroenterology. 2010. PMID: 19818785
Management of ulcerative colitis and Crohn's disease.
Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P. Baert F, et al. Among authors: van assche g. Acta Clin Belg. 2004 Sep-Oct;59(5):304-14. doi: 10.1179/acb.2004.045. Acta Clin Belg. 2004. PMID: 15641402 Review.
Anti-TNF agents in Crohn's disease.
Van Assche G, Rutgeerts P. Van Assche G, et al. Expert Opin Investig Drugs. 2000 Jan;9(1):103-11. doi: 10.1517/13543784.9.1.103. Expert Opin Investig Drugs. 2000. PMID: 11060664 Review.
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Among authors: van assche g, van gossum a. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256 Free article.
Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P, Van Assche G, Vermeire S. Rutgeerts P, et al. Among authors: van assche g. Gastroenterology. 2004 May;126(6):1593-610. doi: 10.1053/j.gastro.2004.02.070. Gastroenterology. 2004. PMID: 15168370 Review.
399 results